The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: NSIP-fibrotic pattern
Publications
Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia.
Cancer. 1971;27(5):1074-80
Busulfan lung. Report of two cases and review of the literature.
The American journal of roentgenology, radium therapy, and nuclear medicine. 1974;120(1):151-6
Diagnosis of busulfan lung by transcatheter biopsy.
Chest. 1973;64(6):771-3
Interstitial pulmonary fibrosis, atypical epithelial changes and bronchiolar cell carcinoma following busulfan therapy.
Cancer. 1968;22(5):1027-32